A green and facile synthesis of an industrially important quaternary heterocyclic intermediates for baricitinib
Abstract Background Baricitinib, with a 2-(1-(ethylsulfonyl)azetidin-3-yl)acetonitrile moiety at N-2 position of the pyrazol skeleton, is an oral and selective reversible inhibitor of the JAK1 and JAK2 and displays potent anti-inflammatory activity. Several research-scale synthetic methods have been...
Main Authors: | Xin Cui, Junming Du, Zongqing Jia, Xilong Wang, Haiyong Jia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-10-01
|
Series: | BMC Chemistry |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13065-019-0639-y |
Similar Items
-
Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib
by: Giuseppe Russo, et al.
Published: (2024-04-01) -
Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
by: Sofia Faria, et al.
Published: (2023-09-01) -
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020-11-01) -
Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro
by: Renlei Feng, et al.
Published: (2025-01-01) -
Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
by: Yuyang Han, et al.
Published: (2022-10-01)